Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

Conditions:   Gastric Adenocarcinoma;   Gastro-esophageal Junction Adenocarcinoma
Interventions:   Drug: Irinotecan;   Drug: Ramucirumab;   Genetic: Blood for angiome profiling;   Genetic: Blood for cfDNA
Sponsors:   Washington University School of Medicine;   Eli Lilly and Company
Not yet recruiting - verified May 2017

http://ift.tt/2p0VqXC